---
title: "HRTX: Q2 2026 net revenue grew 9% sequentially, but full-year guidance was withdrawn amid legal uncertainty"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295405345.md"
description: "Q2 2026 net revenue rose 9% sequentially to $37.7 million, with Acute Care franchise revenue up 43.9% year-over-year, while Oncology Supportive Care declined. Full-year guidance was withdrawn due to patent litigation, and strategic alternatives are being considered.Original document: Heron Therapeutics, Inc. [HRTX] SEC 8-K Current Report — Aug. 10 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-10T12:11:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295405345.md)
  - [en](https://longbridge.com/en/news/295405345.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295405345.md)
generator: "portal-rs"
---

# HRTX: Q2 2026 net revenue grew 9% sequentially, but full-year guidance was withdrawn amid legal uncertainty

Q2 2026 net revenue rose 9% sequentially to $37.7 million, with Acute Care franchise revenue up 43.9% year-over-year, while Oncology Supportive Care declined. Full-year guidance was withdrawn due to patent litigation, and strategic alternatives are being considered.

Original document: Heron Therapeutics, Inc. \[HRTX\] SEC 8-K Current Report — Aug. 10 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [HRTX.US](https://longbridge.com/en/quote/HRTX.US.md)

## Related News & Research

- [Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook](https://longbridge.com/en/news/295404922.md)
- [CHWY: Q2 2026 delivered record customer metrics, strong margins, and $200M in share repurchases](https://longbridge.com/en/news/298446411.md)
- [NBIX: Multi-product growth, robust pipeline, and strategic adaptation position for long-term success](https://longbridge.com/en/news/298609980.md)
- [Inter Parfums announces availability of 2026 half-year report](https://longbridge.com/en/news/298413126.md)
- [ITP: Sales fell 7.3% but margins improved, with resilient brand performance amid global headwinds](https://longbridge.com/en/news/298446814.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**